Discovery of selective RIO2 kinase small molecule ligand

Biochimica et Biophysica Acta - Proteins and Proteomics

Volumn 1854, Issue 10, 2015, Pages 1630-1636

  Varin, Thibault ^a   Godfrey, Alexander G ^a   Masquelin, Thierry ^a   Nicolaou, Christos A ^a   Evans, David A ^a   Vieth, Michal ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

Abbreviations RIO right open reading frame; aPKs atypical protein kinases; ASPL automated synthesis and purification laboratory; COX Cyclooxygenase; ePKs eukaryotic protein kinases; PLC Proximal Lilly Collection; rRNA ribosomal RNA

Indexed keywords

5 [(5 FLUORO 1,2 DIHYDRO 2 OXO 3H INDOL 3 YLIDENE)METHYL] N (2 HYDROXY 3 MORPHOLINOPROPYL) 2,4 DIMETHYL 1H PYRROLE 3 CARBOXAMIDE; ANTIINFLAMMATORY AGENT; CYCLOOXYGENASE 1 INHIBITOR; CYCLOOXYGENASE 2 INHIBITOR; DIPHENPYRAMIDE; MIDOSTAURIN; PBCHM 17249003; PBCHM 17395068; PBCHM 17399864; PBCHM 24238955; PBCHM 25336050; PBCHM 25348574; PBCHM 35023250; PBCHM 4680899; PBCHM 4744022; PBCHM 58447945; PBCHM 70116143; PHOSPHOTRANSFERASE; PHOSPHOTRANSFERASE INHIBITOR; RIO2 KINASE; RIO2 KINASE INHIBITOR; SUNITINIB; UNCLASSIFIED DRUG; ACETAMIDE DERIVATIVE; CELL CYCLE PROTEIN; LIGAND; PROTEIN KINASE INHIBITOR; PROTEIN SERINE THREONINE KINASE; RIO2 PROTEIN, HUMAN;

ARTICLE; ASSAY; BINDING AFFINITY; BIOSYNTHESIS; CELL CYCLE REGULATION; DRUG DEVELOPMENT; DRUG IDENTIFICATION; DRUG MARKETING; DRUG SELECTIVITY; DRUG STABILITY; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME ACTIVITY; ENZYME INHIBITION; KINASE ASSAY; PRIORITY JOURNAL; RIBOSOME; ANTAGONISTS AND INHIBITORS; CHEMICAL STRUCTURE; CHEMISTRY; DRUG EFFECTS; HUMAN; METABOLISM;

ACETAMIDES; CELL CYCLE PROTEINS; HUMANS; LIGANDS; MOLECULAR STRUCTURE; PROTEIN KINASE INHIBITORS; PROTEIN-SERINE-THREONINE KINASES; RIBOSOMES;

EID: 84942079532     PISSN: 15709639     EISSN: 18781454     Source Type: Journal    
DOI: 10.1016/j.bbapap.2015.04.006     Document Type: Article

References (30)

1. MeSH Protein Kinases http://www.ncbi.nlm.nih.gov/mesh/68011494 2014
2. N.A. LaRonde The ancient microbial RIO kinases J. Biol. Chem. 289 2014 9488 9492
3. N. LaRonde-LeBlanc, and A. Wlodawer A family portrait of the RIO kinases J. Biol. Chem. 280 2005 37297 37300
4. N. LaRonde-LeBlanc, and A. Wlodawer Crystal structure of A. fulgidus Rio2 defines a new family of serine protein kinases Structure 12 2004 1585 1594
5. N. Laronde-Leblanc, T. Guszczynski, T. Copeland, and A. Wlodawer Structure and activity of the atypical serine kinase Rio1 FEBS J. 272 2005 3698 3713
6. N. LaRonde-LeBlanc, and A. Wlodawer The RIO kinases: an atypical protein kinase family required for ribosome biogenesis and cell cycle progression Biochim. Biophys. Acta 1754 2005 14 24
7. E. Vanrobays, J.P. Gelugne, P.E. Gleizes, and M. Caizergues-Ferrer Late cytoplasmic maturation of the small ribosomal subunit requires RIO proteins in Saccharomyces cerevisiae Mol. Cell. Biol. 23 2003 2083 2095
8. T.H. Geerlings, A.W. Faber, M.D. Bister, J.C. Vos, and H.A. Raue Rio2p, an evolutionarily conserved, low abundant protein kinase essential for processing of 20 S Pre-rRNA in Saccharomyces cerevisiae J. Biol. Chem. 278 2003 22537 22545
9. I. Zemp, T. Wild, M.F. O'Donohue, F. Wandrey, B. Widmann, P.E. Gleizes, and U. Kutay Distinct cytoplasmic maturation steps of 40S ribosomal subunit precursors require hRio2 J. Cell Biol. 185 2009 1167 1180
10. D.K. Chouhan, A. Sharon, and C. Bal Molecular and structural insight into Plasmodium falciparum RIO2 kinase J. Mol. Model. 19 2013 485 496
11. C.J. Leonard, L. Aravind, and E.V. Koonin Novel families of putative protein kinases in bacteria and archaea: evolution of the "eukaryotic" protein kinase superfamily Genome Res. 8 1998 1038 1047
12. G. Manning, D. Whyte, R. Martinez, T. Hunter, and S. Sudarsanam The protein kinase complement of the human genome Science 298 2002 1912 1934
13. M. Angermayr, and W. Bandlow RIO1, an extraordinary novel protein kinase FEBS Lett. 524 2002 31 36
14. N. LaRonde-LeBlanc, T. Guszczynski, T. Copeland, and A. Wlodawer Autophosphorylation of Archaeoglobus fulgidus Rio2 and crystal structures of its nucleotide-metal ion complexes FEBS J. 272 2005 2800 2810
15. S. Ferreira-Cerca, V. Sagar, T. Schafer, M. Diop, A.M. Wesseling, H. Lu, E. Chai, E. Hurt, and N. LaRonde-LeBlanc ATPase-dependent role of the atypical kinase Rio2 on the evolving pre-40S ribosomal subunit Nat. Struct. Mol. Biol. 19 2012 1316 1323
16. T. Liu, M. Deng, J. Li, X. Tong, Q. Wei, and X. Ye Phosphorylation of right open reading frame 2 (Rio2) protein kinase by polo-like kinase 1 regulates mitotic progression J. Biol. Chem. 286 2011 36352 36360
17. R.D. Read, T.R. Fenton, G.G. Gomez, J. Wykosky, S.R. Vandenberg, I. Babic, A. Iwanami, H. Yang, W.K. Cavenee, P.S. Mischel, F.B. Furnari, and J.B. Thomas A kinome-wide RNAi screen in Drosophila glia reveals that the RIO kinases mediate cell proliferation and survival through TORC2-Akt signaling in glioblastoma PLoS Genet. 9 2013 e1003253
18. P. Ward, L. Equinet, J. Packer, and C. Doerig Protein kinases of the human malaria parasite Plasmodium falciparum: the kinome of a divergent eukaryote BMC Genomics 5 2004 79
19. M.I. Davis, J.P. Hunt, S. Herrgard, P. Ciceri, L.M. Wodicka, G. Pallares, M. Hocker, D.K. Treiber, and P.P. Zarrinkar Comprehensive analysis of kinase inhibitor selectivity Nat. Biotechnol. 29 2011 1046 1051
20. J. Zhang, P.L. Yang, and N.S. Gray Targeting cancer with small molecule kinase inhibitors Nat. Rev. Cancer 9 2009 28 39
21. J.J. Sutherland, C. Gao, S. Cahya, and M. Vieth What general conclusions can we draw from kinase profiling data sets? Biochim. Biophys. Acta 1834 2013 1425 1433
22. C. Gao, S. Cahya, C.A. Nicolaou, J. Wang, I.A. Watson, D.J. Cummins, P.W. Iversen, and M. Vieth Selectivity data: assessment, predictions, concordance, and implications J. Med. Chem. 56 2013 6991 7002
23. A.G. Godfrey, T. Masquelin, and H. Hemmerle A remote-controlled adaptive medchem lab: an innovative approach to enable drug discovery in the 21st Century Drug Discov. Today 18 2013 795 802
24. S. Caliari, L. Alfieri, G.B. Gervasi, M.P. Sangiovanni, and F. Scrollini Pharmacological properties of the anti-inflammatory agent pyridyl-biphenylyl-acetamide (diphenpyramide) Arzneimittelforschung 27 1977 2086 2093
25. J.G. Lombardino Chapter 18. Newer agents for the treatment of arthritis H.C. Frank, Annual Reports in Medicinal Chemistry 1978 Academic Press 167 178
26. J.R. Kiefer, J.L. Pawlitz, K.T. Moreland, R.A. Stegeman, W.F. Hood, J.K. Gierse, A.M. Stevens, D.C. Goodwin, S.W. Rowlinson, L.J. Marnett, W.C. Stallings, and R.G. Kurumbail Structural insights into the stereochemistry of the cyclooxygenase reaction Nature 405 2000 97 101
27. S. Xu, D.J. Hermanson, S. Banerjee, K. Ghebreselasie, G.M. Clayton, R.M. Garavito, and L.J. Marnett Oxicams bind in a novel mode to the cyclooxygenase active site via a two-water-mediated H-bonding Network J. Biol. Chem. 289 2014 6799 6808
28. DiscoverX KINOMEscan - word's largest kinase assay panel http://www.discoverx.com/services/drug-discovery-development-services/kinase-profiling/kinomescan 2014
29. J. Blanc, R. Geney, and C. Menet Type II kinase inhibitors: an opportunity in cancer for rational design Anti Cancer Agents Med. Chem. 13 2013 731 747
30. C.N. Johnson, V. Berdini, L. Beke, P. Bonnet, D. Brehmer, J.E. Coyle, P.J. Day, M. Frederickson, E.J.E. Freyne, R.A.H.J. Gilissen, C.C.F. Hamlett, S. Howard, L. Meerpoel, R. McMenamin, S. Patel, D.C. Rees, A. Sharff, F. Sommen, T. Wu, and J.T.M. Linders Fragment-based discovery of type I inhibitors of maternal embryonic leucine zipper kinase ACS Med. Chem. Lett. 6 2015 25 30